KRAS any mutation — panitumumab resistance
Gene: KRAS · Type: mutation
Indications: Colorectal cancer
Linked CIViC Profile: KRAS MUTATION
Evidence Level Distribution
Level A: 2Level B: 26Level C: 1Level D: 15Level E: 1
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| A | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Selumetinib,Docetaxel | 5 |
| A | Predictive | Supports | Resistance | Colorectal Cancer | Panitumumab,Cetuximab | 5 |
| D | Predictive | Supports | Sensitivity/Response | Cancer | Trametinib | 4 |
| D | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | B-Raf/VEGFR-2 Inhibitor RAF265,Selumetinib | 4 |
| D | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Trametinib,Afatinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Selumetinib,Docetaxel | 4 |
| D | Predictive | Supports | Sensitivity/Response | Pancreatic Adenocarcinoma | SCH772984,PI3Kbeta Inhibitor AZD8186 | 4 |
| B | Predictive | Supports | Resistance | Colorectal Cancer | Chemotherapy,Bevacizumab | 4 |
| B | Prognostic | Supports | Poor Outcome | Lung Adenocarcinoma | 4 | |
| B | Predictive | Supports | Resistance | Colorectal Cancer | Cetuximab,Chemotherapy | 4 |
| B | Predictive | Does Not Support | Sensitivity/Response | Lung Non-small Cell Carcinoma | Trametinib | 4 |
| B | Predictive | Does Not Support | Sensitivity/Response | Lung Non-small Cell Carcinoma | Erlotinib,Selumetinib | 4 |
| D | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Palbociclib,Binimetinib | 4 |
| B | Predictive | Does Not Support | Sensitivity/Response | Lung Non-small Cell Carcinoma | Docetaxel,Erlotinib | 4 |
| B | Predictive | Does Not Support | Sensitivity/Response | Lung Non-small Cell Carcinoma | Docetaxel | 4 |
| D | Predictive | Supports | Sensitivity/Response | Ovarian Cancer | Decitabine | 3 |
| D | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Cetuximab,Dasatinib | 3 |
| B | Predictive | Does Not Support | Resistance | Lung Non-small Cell Carcinoma | MEK Inhibitor RO4987655 | 3 |
| D | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Selumetinib,Teprotumumab | 3 |
| D | Predictive | Supports | Sensitivity/Response | Cancer | G-573,MEK Inhibitor GDC-0623 | 3 |